MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03602nam a22004457a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
170411s20162016 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
0195-668X |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
27190094 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. |
| 251 ## - Source |
|---|
| Source |
European Heart Journal. 37(35):2701-9, 2016 Sep 14 |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Eur Heart J. 37(35):2701-9, 2016 Sep 14 |
| 253 ## - Journal Name |
|---|
| Journal name |
European heart journal |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2016 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2017 |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2017-05-24 |
| 501 ## - WITH NOTE |
|---|
| Local holdings |
Available online from MWHC library: 1996 - present (after 1 year), Available in print through MWHC library: 1999 - 2006 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
AIMS: Metal absorbable scaffolds constitute a conceptually attractive alternative to polymeric scaffolds. Promising 6-month outcomes of a second-generation drug-eluting absorbable metal scaffold (DREAMS 2G), consisting of an absorbable magnesium scaffold backbone, have been reported. We assessed the 12-month safety and performance of this novel device. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CLINICALTRIALSGOV IDENTIFIER: NCT01960504. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSION: The novel drug-eluting metal absorbable scaffold DREAMS 2G showed a continuous favourable safety profile up to 12 months and stable angiographic parameters between 6 and 12 months. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Copyright (c) The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
METHODS AND RESULTS: The prospective, international, multi-centre, first-in-man BIOSOLVE-II trial enrolled 123 patients with up to two de novo lesions with a reference diameter between 2.2 and 3.7 mm. All patients were scheduled for angiographic follow-up at 6 months, and-if subjects consented-at 12 months. Dual antiplatelet therapy was recommended for 6 months. Quantitative coronary angiography (QCA) parameters remained stable from 6 to 12 months [paired data of 42 patients: in-segment late lumen loss 0.20 +/- 0.21 mm vs. 0.25 +/- 0.22 mm, P = 0.117, DELTA 0.05 +/- 0.21 mm (95% CI: -0.01;0.12); in-scaffold late lumen loss 0.37 +/- 0.25 mm vs. 0.39 +/- 0.27 mm, P = 0.446, DELTA 0.03 +/- 0.22 (95% CI: -0.04;0.10), respectively]. Intravascular ultrasound and optical coherence tomography findings corroborated the QCA results. Target lesion failure occurred in four patients (3.4%), consisting of one death of unknown cause, one target-vessel myocardial infarction, and two clinically driven target lesion revascularization. No additional event occurred beyond the 6-month follow-up. During the entire follow-up of 12 months, none of the patients experienced a definite or probable scaffold thrombosis. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Drug-Eluting Stents |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Absorbable Implants |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Coronary Angiography |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Coronary Artery Disease |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Metals |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Prospective Studies |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Sirolimus |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Treatment Outcome |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Heart & Vascular Institute |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Garcia-Garcia, Hector M |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Waksman, Ron |
| 790 ## - Authors |
|---|
| All authors |
Abizaid A, Christiansen EH, Eeckhout E, Escaned J, Garcia-Garcia HM, Haude M, Ince H, Kaiser C, Lemos PA, Lim ST, Neumann FJ, Onuma Y, Toelg R, von Birgelen C, Waksman R, Wijns W |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1093/eurheartj/ehw196">https://dx.doi.org/10.1093/eurheartj/ehw196</a> |
| Public note |
https://dx.doi.org/10.1093/eurheartj/ehw196 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
